Maternal Thyroid Medications and Neonatal Thyroid Function: PTU and Methimazole Effects

Introduction: Thyroid Disease in Pregnancy and Neonatal Consequences

Thyroid disorders are the second most common endocrine condition in pregnancy after gestational diabetes, affecting approximately 2-5% of pregnant women. In India, subclinical hypothyroidism is particularly prevalent, affecting 10-15% of pregnant women in some regional studies. Both hyperthyroidism and hypothyroidism, and critically, the medications used to treat them, have direct implications for neonatal thyroid function and neurodevelopment.

This guide examines the effects of antithyroid drugs (propylthiouracil and methimazole) on the neonate, discusses neonatal thyrotoxicosis from transplacental antibody transfer, reviews levothyroxine safety, and provides monitoring protocols aligned with American Thyroid Association (ATA), FOGSI, and NNF India guidelines. Understanding the complex interplay between maternal thyroid disease, medication effects, and neonatal thyroid physiology is essential for neonatologists and pediatricians managing these infants.

Thyroid Physiology in Pregnancy and the Fetus

Maternal Thyroid Adaptation

Pregnancy induces significant changes in maternal thyroid physiology that affect drug dosing and fetal thyroid development.

• HCG-mediated thyroid stimulation: Human chorionic gonadotropin (hCG), structurally similar to TSH, stimulates the maternal thyroid in the first trimester, physiologically lowering TSH to 0.1-0.4 mIU/L. This can be confused with hyperthyroidism.
• Increased thyroxine-binding globulin: Estrogen-mediated TBG elevation increases total T4 and T3 by 50%, necessitating free hormone measurement for accurate assessment.
• Increased iodine clearance: Renal iodide clearance doubles during pregnancy, increasing iodine requirements to 250 mcg/day (WHO recommendation).
• Increased levothyroxine requirement: Women on levothyroxine typically need a 30-50% dose increase during pregnancy, ideally initiated at pregnancy confirmation.

Fetal Thyroid Development

The fetal thyroid begins functioning at 12-14 weeks of gestation, but does not reach full autonomy until approximately 20 weeks. Before this, the fetus depends on maternal thyroid hormones crossing the placenta for brain development. Key fetal thyroid milestones include thyroid gland organogenesis (weeks 7-12), iodine trapping initiation (week 12), T4 synthesis begins (week 14), hypothalamic-pituitary-thyroid axis maturation (weeks 20-30), and full thyroid autonomy (after 30 weeks). This timeline has critical implications for medication effects: antithyroid drugs given early suppress the developing fetal thyroid during a period of brain vulnerability.

Antithyroid Drugs in Pregnancy

Propylthiouracil (PTU)

PTU inhibits thyroid peroxidase (blocking T4 and T3 synthesis) and also inhibits peripheral T4-to-T3 conversion. It crosses the placenta in lower concentrations than methimazole due to higher protein binding, historically making it the preferred agent in pregnancy.

Parameter	PTU Details
Dose range in pregnancy	50-300 mg/day in divided doses (every 8 hours)
Placental transfer	Moderate (lower than methimazole due to protein binding)
Preferred trimester	First trimester (avoids methimazole embryopathy)
Key maternal risk	Hepatotoxicity (including fulminant liver failure, rare)
Neonatal effects	Transient hypothyroidism (1-5%), goiter (rare at low doses)
Breastfeeding	Safe; minimal transfer (less than 1% of dose)

Methimazole (Carbimazole)

Methimazole, and its prodrug carbimazole used in Indian practice, is the more potent antithyroid agent with a longer half-life allowing once-daily dosing. However, first-trimester exposure is associated with methimazole embryopathy, a pattern including aplasia cutis (scalp defect), choanal atresia, esophageal atresia, and facial dysmorphism.

• Dose range: 5-30 mg/day (once or twice daily); carbimazole doses approximately 1.5 times higher
• Placental transfer: Higher than PTU; fetal thyroid suppression more likely
• Preferred trimester: Second and third trimesters (after organogenesis complete)
• Neonatal effects: Transient hypothyroidism, scalp defects with first-trimester exposure, goiter
• Breastfeeding: Safe at doses up to 20-30 mg/day; minimal neonatal thyroid effect

Recommended Switching Strategy

The ATA and most international guidelines now recommend a trimester-based switching strategy: PTU in the first trimester (to avoid methimazole embryopathy) and methimazole from the second trimester onward (to avoid PTU hepatotoxicity risk). The switch is made at 12-16 weeks, with dose equivalence of approximately PTU 100 mg equals methimazole 7-10 mg. This strategy is endorsed by FOGSI, though some Indian practitioners prefer continuing PTU throughout pregnancy for simplicity.

Neonatal Thyrotoxicosis: A Medical Emergency

Pathophysiology

Neonatal thyrotoxicosis occurs when thyroid-stimulating immunoglobulins (TSI) from a mother with Graves disease cross the placenta and stimulate the neonatal thyroid. It affects 1-2% of neonates born to mothers with active or past Graves disease, even mothers who have undergone thyroidectomy (as antibodies persist). TSI levels greater than 3 times the upper limit of normal in the third trimester predict neonatal thyrotoxicosis risk.

Clinical Presentation

Neonatal thyrotoxicosis may present immediately at birth or be delayed by 3-10 days if maternal antithyroid drugs are masking the condition. As maternal drug levels fall in the neonate while maternal antibodies persist, thyrotoxicosis unmaskes. Clinical features include persistent tachycardia (heart rate above 160 bpm), irritability, poor weight gain despite adequate feeding, goiter, exophthalmos, flushing, diarrhea, hepatosplenomegaly, thrombocytopenia, and rarely high-output cardiac failure.

Treatment Protocol

1. Methimazole: 0.5-1 mg/kg/day orally in 2-3 divided doses to block thyroid hormone synthesis
2. Propranolol: 1-2 mg/kg/day in 3 divided doses to control tachycardia and sympathetic symptoms
3. Lugol's iodine: 1 drop (6.3 mg iodine) every 8 hours for severe cases, to acutely block thyroid hormone release through the Wolff-Chaikoff effect
4. Prednisolone: 2 mg/kg/day in severe or refractory cases, to reduce T4-to-T3 conversion and suppress antibody effects
5. Cardiac monitoring: Continuous cardiorespiratory monitoring, echocardiography if heart failure suspected

Neonatal thyrotoxicosis is self-limiting, resolving within 2-3 months as maternal TSI antibodies are cleared from the neonatal circulation (half-life approximately 2-3 weeks). Treatment is typically needed for 4-12 weeks.

Transient Neonatal Hypothyroidism from Antithyroid Drugs

Mechanism and Incidence

Maternal antithyroid drugs cross the placenta and suppress fetal thyroid function, causing transient neonatal hypothyroidism in 1-5% of exposed neonates. The risk increases with higher maternal doses (methimazole above 15 mg/day, PTU above 200 mg/day) and third-trimester exposure when the fetal thyroid is most active. Affected neonates may present with elevated TSH on newborn screening, with or without clinical symptoms.

Clinical Management

Transient hypothyroidism from antithyroid drug exposure typically resolves within 1-3 weeks as the drug is cleared from the neonatal circulation. Management includes monitoring thyroid function (TSH, free T4) at birth, day 3-5, and day 10-14. If TSH remains elevated above 20 mIU/L with low free T4, initiate levothyroxine supplementation. Reassess at 3 months to determine if hypothyroidism has resolved (transient) or persists (suggesting permanent congenital hypothyroidism unrelated to maternal medication).

Levothyroxine in Pregnancy: Neonatal Safety

Levothyroxine (T4) replacement for maternal hypothyroidism is entirely safe for the neonate. T4 has minimal placental transfer at physiological concentrations (only 20-30% of maternal T4 reaches the fetus), and the transferred hormone supports critical fetal brain development. The far greater risk is inadequate maternal thyroid replacement, which can cause fetal neurodevelopmental impairment. In India, where subclinical hypothyroidism affects 10-15% of pregnant women, universal TSH screening in early pregnancy is recommended by FOGSI.

Indian Practice Point: Many Indian women on levothyroxine have subtherapeutic dosing during pregnancy because dose increases are not initiated early enough. FOGSI recommends increasing levothyroxine by 30% as soon as pregnancy is confirmed (practically, adding 2 extra doses per week of the current dose), with TSH monitoring every 4-6 weeks throughout pregnancy. Target TSH is trimester-specific: below 2.5 mIU/L in the first trimester, below 3.0 mIU/L in the second and third trimesters.

Newborn Thyroid Screening in India

National Program and Coverage

India's National Newborn Screening Programme includes congenital hypothyroidism as a target condition, using heel-prick TSH measurement. However, coverage remains incomplete, with only 25-30% of newborns screened nationally. In this context, maternal thyroid disease history becomes even more critical for identifying at-risk neonates who may be missed by incomplete screening programs.

Enhanced Screening for High-Risk Neonates

For neonates born to mothers with thyroid disease, the standard newborn screening TSH may be insufficient. NNF India recommends the following enhanced screening protocol.

Maternal Condition	Neonatal Testing	Timing	Repeat Testing
Graves disease (active or past)	TSH, free T4, TSI	Cord blood + day 3-5	Day 10-14 (delayed thyrotoxicosis)
On antithyroid drugs	TSH, free T4	Cord blood + day 3-5	Day 10-14, 1 month
Hypothyroidism on levothyroxine	Standard NBS TSH	Day 3-5	Only if abnormal
Hashimoto's thyroiditis	TSH, free T4	Day 3-5	1 month (blocking antibodies)

Iodine Status and Neonatal Thyroid Function

India has made significant progress in iodine deficiency elimination through the National Iodine Deficiency Disorders Control Programme. However, pockets of iodine deficiency persist in sub-Himalayan regions, tribal areas, and flood-prone plains. Maternal iodine deficiency directly impairs fetal thyroid function and brain development. Conversely, excess iodine from contrast media, amiodarone, or povidone-iodine antiseptics can cause transient neonatal hypothyroidism through the Wolff-Chaikoff effect. Neonatal units should avoid excessive iodine-based skin antiseptics in preterm infants due to percutaneous absorption risk.

Long-Term Developmental Follow-Up

Neonates with transient thyroid dysfunction from maternal medication require thyroid function monitoring at 3 and 6 months to confirm resolution. Those with neonatal thyrotoxicosis need monitoring until antibody clearance is confirmed. All neonates of mothers with thyroid disease benefit from developmental screening at standard intervals, as both maternal thyroid dysfunction and neonatal thyroid disturbances can subtly impact neurodevelopment. HEAMAC neonatal care resources support structured home-based follow-up and developmental monitoring for neonates requiring ongoing thyroid surveillance.

Conclusion: Integrated Maternal-Neonatal Thyroid Care

Managing maternal thyroid disease in pregnancy requires close collaboration between endocrinologists, obstetricians, and neonatologists. The trimester-based antithyroid drug strategy (PTU in the first trimester, methimazole thereafter) minimizes both embryopathy and hepatotoxicity risks. Neonatal teams must anticipate both transient hypothyroidism from antithyroid drug transfer and delayed thyrotoxicosis from TSI antibody persistence. With structured neonatal thyroid screening, timely treatment, and developmental follow-up, outcomes for neonates of thyroid-affected mothers are excellent.